Fengbo Jin
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.
Journal: Cancer cell international
Published: October 28, 2025
CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments.
Journal: Clinical and experimental medicine
Published: June 05, 2025
Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learning.
Journal: Cell reports. Medicine
Published: April 03, 2025
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.
Journal: Cancer cell international
Published: November 01, 2024
Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia.
Journal: European journal of medical research
Published: August 15, 2024
SFXN3 is a Prognostic Marker and Promotes the Growth of Acute Myeloid Leukemia.
Journal: Cell biochemistry and biophysics
Published: May 17, 2024
Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.
Journal: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica
Published: February 23, 2024
Decoding prognostic factors in SARS-CoV-2 complications among patients with hematological disorders.
Decoding prognostic factors in SARS-CoV-2 complications among patients with hematological disorders.
Journal: Clinics (Sao Paulo, Brazil)
Published: December 20, 2023
SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphoma.
Journal: BMC medical genomics
Published: October 31, 2023
Knowledge, attitude, and practice toward leukemia in the general population and among family members of patients with leukemia: A cross-sectional study.
Journal: Heliyon
Published: September 25, 2023
SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.
Journal: Current gene therapy
Published: February 21, 2023
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Journal: Signal transduction and targeted therapy
Published: July 05, 2022
Last Updated: 09/26/2026